Imexpharm

Imexpharm EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm (IMP.VN) as of Oct 27, 2026 is 16.62 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 16.58 % — a change of 0.24% (higher).

EBIT/Assets

16.62 %

YoY

0.24%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm is 2025 16.62 % . Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm was 2024 16.58 % . It decreases by 0.24% higher compared to the previous year.

The Imexpharm EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
8.93 VND
Jan 1, 2019
10.99 VND
Jan 1, 2020
12.52 VND
Jan 1, 2021
10.78 VND
Jan 1, 2022
13.02 VND
Jan 1, 2023
15.93 VND
Jan 1, 2024
16.58 VND
Jan 1, 2025
16.62 VND
The Imexpharm EBIT/Assets history
YEAREBIT/AssetsYoY
16.62 %+0.24%
16.58 %+4.10%
15.93 %+22.30%
13.02 %+20.76%
10.78 %-13.90%
12.52 %+13.93%
10.99 %+23.13%
8.93 %+22.64%
7.28 %-29.52%
10.33 %+6.12%
9.73 %-1.48%
9.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm is 16.62 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm changed from 16.58 % to 16.62 %, representing a 0.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Imexpharm

All Key Metrics — Imexpharm